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ABSTRACT 
Background:  Elevated  serum  cholesterol  in  humans  is  generally  a  risk  factor 
correlated  with  the  development  of  atherosclerosis  (AS).  Lactobacillus  casei  has 
been demonstrated to have the potential to reduce human serum cholesterol levels. 
The  purpose  of  this  study  was  to  evaluate  the  anti-atherosclerotic  effect  of 
Lactobacillus casei (Strain Shirota) in apoE-deficient mice. 
 
Methods: A total of 60 male ApoE-deficient mice of 4 weeks age, were randomly divided 
into 4 groups of 15 each group and matched for body weight. Four groups of apoE-deficient 
mice consumed one of the following diet: AIN-93G purified diet (n=15); AIN-93G purified 
diet with Lactobacillus casei (Strain Shirota; 0.5 mL of 10
8 cfu/mL， n=15); AIN-93G purified 
diet  with  Lactobacillus  casei  (Strain  Shirota;  0.5  mL  of  10
10 cfu/mL，n=15);  AIN-93G 
purified diet with Lactobacillus casei (Strain Shirota; 0.5 mL of 10
12 cfu/mL，n=15).   
 
Results: After 16 weeks intervention, the areas of atherosclerotic plaques in the aortic sinus 
were determined. Plaques  were much more severe in  control  group than in  lactobacillus 
casei-treated groups (P < 0.05). The plaque area of aortic sinus in mice fed lactobacillus casei 
with 0.5 mL of 10
8, 10
10, or 10
12 cfu/mL was 44.61%, 56.01%, 82.58% less compared with 
control group, respectively. Compared with control group, total cholesterol accumulation in 
aortas and livers showed a significant reduction in mice fed with lactobacillus casei (P < 
0.05). Addition of lactobacillus casei also ameliorated serum lipid profile by decreasing total 
serum cholesterol and increasing HDL cholesterol concentration.   
 
Conclusions: lactobacillus casei significantly improved lipid profile and reduced cholesterol Functional Foods in Health and Disease 2014; 4(4):147- 158                                                 Page 148 of 158 
accumulation in liver and aorta, leading the inhibition of the formation of atherosclerotic 
lesion.   
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INTRODUCTION: 
Atherosclerosis (AS) is a complex and multifactorial disease, the etiology of which involves 
both  genetic  and  environmental  factors.  A  large  number  of  studies  revealed  that 
atherosclerotic cardiovascular disease is the major cause of death in the United States, Europe 
and some of Asia society [1-2]. Atherosclerosis is the main etiopathogenic process that causes 
Coronary  artery  disease  (CHD).  CHD  is  the  principal  individual  cause  of  mortality  and 
morbidity worldwide. Disability-adjusted life years (DALYs) which is calculated as the sum 
of years of life lost and years lived with disability is considered as a new metric to measure 
disease  burden.  A  recent  report  on  the  Global  Burden  of  Disease,  indicates  that  CHD 
accounted for the largest proportion of DALYs due to a single cause worldwide in 2010, 
explaining 5% of the total number of DALYS[3]. Hypercholesterolemia is an important risk 
factor  associated  with  atherosclerosis  and  CHD  [4].  In  the  United  States,  with  the  ≥ 
5.18mmol/L definition, the age-adjusted mean hypercholesterolemia prevalence in 2000 to 
2002 was 54.9% for men and 46.5% for women [5]. 
Few  therapeutic  measures  were  effective  in  treatment  of  AS  due  to  its  pathological 
complexity until now. Thus, it is essential to control the major risk factors for AS. Dietary 
mode and life style are now considered tightly related to the atherogenesis, in which the 
improvement of eating habits and dietary model may lead to the decline in morbidity of AS 
[4,6]. The lactobacilli as the beneficial probiotics, are important inhabitants of the intestinal 
tract  of  human  and  animals,  affecting  host  metabolic  reactions,  supporting  a  balance  of 
human  ecosystem.  Considerable  evidence  has  implicated  lactobacilli  in  a  number  of 
potentially  beneficial  roles.  Several  studies  reported  that  lactobacilli  have  the 
hypocholesterolemia  effects  in  animals  [7-8].  Some  studies  in  vitro  have  shown  that 
beneficial bacteria can remove cholesterol from culture medium, much attention has been 
given  to  the  cholesterol-lowering  potential  of  probiotics  in  humans  [9-10].  Furthermore, 
lactobacilli strains were considered to have the property of inhibiting oxidation [10-11].   
As  it  is  well  known  that  hypercholesterolemia  is  involved  in  the  progression  of 
atherosclerosis  or  CHD.  Lowering  hypercholesterolemia  and  antioxidative  effects  by 
lactobacilli is expected to contribute to the inhibition of atherosclerosis. However, there is so 
far  no  study  demonstrating  that  supplementation  of  lactobacilli  could  reduce  the 
atherosclerotic plaque formation in human or animals. The present study is to investigate the 
influence of supplementation of Lactobacillus casei on atherosclerotic plaque formation in 
apoE-deficient  mice,  and  further  to  explore  whether  Lactobacillus  casei  supplementation 
induced-reduction of hypercholesterolemia, total cholesterol accumulation in aortas and livers 
contribute to its inhibition of atherosclerotic lessons in the animals.   
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MATERIALS AND METHODS 
Animals and Diets: ApoE-deficient mice on a C57BL/6J background were purchased 
from Jackson Laboratories in USA, bred, and maintained under conventional housing 
conditions  in  our  animal  facility.  Lactobacillus  casei  Shirota  strain  YIT9029  was 
from Yakult Honsha Co., Ltd (Japan). A total of 60 male ApoE-deficient mice of 4 
weeks age, were randomly divided into 4 groups of 15 each group and matched for 
body weight. All the groups received purified diet based on the AIN-93G formulation 
[11]. The  three  experimental  groups  were  given  by  gavage  once  a  day  with  same 
volume(0.5ml) of different doses of Lactobacillus casei(10
8,10
10 and 10
12 cfu/mL). 
The  control  group  didn’t  receive  gavage.  All  procedures  using  animals  were  in 
accordance  with  the  protocol  approved  by  the  standing  committee  of  Sun  Yat-sen 
University. All the mice were housed in sterile filter-top cages at 24 ℃ with a 12 h 
light-dark cycle. Animals had ad libitum access to food and autoclaved water. The 
experiment  lasted  16  weeks  and  animal  body-weight  were  recorded  weekly 
throughout the experiment. The average amount of dietary intake by each mouse was 
≈ 2.8 g/d in each group. At the end of experiment, all mice were deprived of food 
overnight and kindly  killed by  withdrawing blood from  retro orbital plexus under 
anesthesia. Serun was prepared by low speed centrifugation at 2800g for 20 min at 
4 ℃ and used to determine the levels of serum lipids profile. The major organs and 
aortas  were  harvested,  washed  with  ice-cold  PBS  and  weighed.  Aortas  and  hearts 
were prepared for morphological and biochemical analysis. The serum samples were 
stored at -80 ℃, heart and aorta samples were stored in liquid nitrogen until used for 
assay. 
 
Atherosclerotic Lesion Area: Quantification of atherosclerotic fatty streaks was done by 
calculating  the  lesion  size  in  the  aortic  sinus  as  previously  described  [13]  with  a  few 
modifications.  Briefly,  the  heart  and  upper  section  of  the  aorta  were  removed  from  the 
animals and the peripheral fat cleaned carefully. The upper section was embedded in OCT 
compound and frozen at –20 ℃. Every other section (10 μm thick) throughout the aortic sinus 
(400 μm) was taken for analysis. The distal portion of the aortic sinus was recognized by the 
three valve cusps which are the junctions of the aorta and the heart. Cryostat sections were 
evaluated  for  fatty  streak  lesions  after  staining  with  Oil  red  O  and  counterstaining  with 
hematoxylin. Each section of the aortic valve was evaluated for Oil red O staining area by 
capturing  images  directly  from  an  RGB  camera  attached  to  an  Olympus  BX-50  light 
microscope and displaying them on a Trinitron RGB monitor. Image analysis was determined 
using Optimas  4.1 software  (Image Processing Solutions). Results  were expressed as  the 
percent of the total cross-sectional vessel wall area (normal+diseased area/section, excluding 
the lumen) stained with Oil red O. 
 
Serum Lipid Profile: Cholesterol is insoluble in water but soluble in lipid, and is transported 
in  the  blood  among  tissues  by  four  lipoproteins:  chylomicron  (CM),  very  low-density Functional Foods in Health and Disease 2014; 4(4):147- 158                                                 Page 150 of 158 
lipoprotein  (VLDL),  low-density  lipoprotein  (LDL)  and  high-density  lipoprotein  (HDL). 
Blood samples were obtained from animals fasted overnight by retroorbital bleeding under 
anesthesia.  Serum  total  cholesterol  (TC)  and  HDL-C  were  measured  using  a  cholesterol 
esterase and cholesterol oxidase assay [14]. Serum LDL-C were determined by Direct LDL™ 
assay (Sigma Diagnostics, St. Louis, MO, USA), measured on a Hitachi 7060 Automatic 
Biochemical Analyser [15]. 
 
Cholesterol Content in Liver: Immediately after animal sacrifice, fresh livers were removed 
from the mice and heat processed at 110 C for 11 h. Weighed dried livers (300 mg) were 
extracted by Folch reagent (chloroform: methanol (2:1, vol:vol)) and stored at -20 C until 
analysis [16]. 
 
Cholesterol Accumulation in Aorta: Immediately following animal sacrifice, the heart of 
each mice was exercised which the aortic arch was dissected from the aortic root to the right 
renal artery and adventitial fat was removed. The aortas were stored on ice in PBS for a 
period not longer than 8 hours and not less than 2 h. Aortic tissue was dried, minced, and 
weighed before removing the lipids by the method of Folch et al [16]. In brief, the aortas 
were homogenized in 2 mL of chloroform: methanol (2:1, vol:vol) and centrifuged at 1700 g 
for 5 min. Two milliliters of supernatant was transferred to a clean test tube, and 0.4 mL of 
0.88%  KCl  was  added  to  separate  the  aqueous  and  lipid  layers.  The  lipid  layer  was 
transferred to another tube, completed dried under N
2 at 37 C, redissolved in 0.2 ml of 100% 
reagent-grade  ethanol  and  stored  at  -20  C  until  the  time  of  assay.  The  total  cholesterol 
content of aortic extracts was determined using an enzymatic fluorometric assay based on a 
modification  of  preciously  described  methods  [17].  Briefly,  for  total  cholesterol 
determination,  0.1  mL  of  the  sample  was  added  to  0.9  mL  assay  solution  (0.1  U/mL 
cholesterol oxidase, 1 U/mL peroxidase, 0.01 U/mL cholesterol ester hydrolase, 0.05% triton 
X-100, 1 mL sodium cholate and 0.6 mL potassium phosphate buffer, PH 7.4) and incubated 
at  37  C  for  1  hour.  Fluorescence  was  measured  adding  a  Shimadzu  R-540 
spectrofluorophotometer  (excitation,  325  nm;  emission,  415  nm).  Samples  for  each  aorta 
were run in duplicate. All values are expressed as nmol/mg aorta (wet weight) for each mouse. 
Means and SD were determined for each group. 
 
Statistics: Results are expressed as means  SD. Data were analyzed by one-factor ANOVA. 
Differences between groups were considered significant if p < 0.05. SPSS10.0 software was 
used for all statistical analysis. 
 
RESULTS: 
Lactobacillus casei Strain Shirota supplementation inhibits atherosclerotic plaque 
formation  in  apoE-deficient  mice:  After  16  weeks  intervention,  the  areas  of 
atherosclerotic plaques in the aortic sinus were determined. Plaques were much more severe 
in control group than in lactobacillus casei-treated groups. The average plaque areas in mice Functional Foods in Health and Disease 2014; 4(4):147- 158                                                 Page 151 of 158 
fed Lactobacillus casei (Strain Shirota) with 10
8, 10
10, 10
12 cfu/mL were lower than that of 
untreated control group (P < 0.05). The plaque area of aortic sinus in mice fed Lactobacillus 
casei was 44.61%, 56.01%, 82.58% less compared  with control group, respectively. This 
result suggests that Lactobacillus casei exhibit anti-atherogenesis (Figure 1). 
 
Figure 1   
（A）Oil red O Staining of Aortic Sinus Sections 
        
A                                      B 
         
C                                       D 
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(A) Mice from different groups were sacrificed after 16 weeks on different diets and their 
hearts were embedded in OCT. Section from the aortic sinus and stained with Oil red O. 
Original magnification×40. 
(B) The extent of atherosclerosis was quantified after 16 weeks. Atherosclerotic lesion 
area in the sinus was measured by staining lesions with Oil-red O. Values are means ± SD, 
n=15. **P < 0.01. 
 
Lactobacillus  casei  Strain  Shirota  supplementation  reduces  serum  lipid  levels: 
Compared  with  control  group,  plasm  levels  of  total  cholesterol,  triglycerides,  LDL 
significantly decreased, while HDL dramatically increased in mice fed with Lactobacillus 
casei (Strain Shirota) with 0.5 mL of 108, 1010, and 1012 cfu/mL (P < 0.05). There was no 
significant difference in the plasma levels of TC, TG, LDL and HLD among lactobacillus 
casei treated groups (P > 0.05). (Figure 2) 
 
Figure 2. Serum Lipid Concentrations in Apolipoprotein E-deficient Mice Fed AIN-93G Diet 
or AIN-93G Diet Supplemented with Lactobacillus casei. 
 
After 16 weeks, compared with control group, plasm levels of total cholesterol, triglycerides, 
LDL  significantly  decreased,  while  HDL  dramatically  increased  in  mice  fed  with   
Lactobacillus casei (Strain Shirota) with 0.5 mL of 10
8, 10
10, and 10
12 cfu/mL (P < 0.05).   
 
Lactobacillus  casei  Strain  Shirota  supplementation  decreases  total  cholesterol 
accumulation  in  aortas  and  livers:  Aortic  and  hepatic  cholesterol  contents  were 
lower  in  the  Lactobacillus  casei-treated  groups  as  compared  with  the  untreated 
control group. Compared with the control group, total cholesterol accumulation in 
aortas and livers showed a significant reduction in mice fed with Lactobacillus casei 
(P  <  0.05).  There  was  no  significant  difference  among  lactobacillus  casei  treated 
groups (P > 0.05). (Figure 3-4) Functional Foods in Health and Disease 2014; 4(4):147- 158                                                 Page 153 of 158 
   
 
 
 
 
 
 
 
 
 
Figure 3. Cholesterol Accumulation in Aortas   
 
After  dissected  extending  from  the  aortic  root  to  the  right  renal  artery,  the  aortas  were 
subjected to lipid extraction by a modified Folch method with chloroform/methanol (2:1, 
vol/vol). Total cholesterol  content of the lipid extract  was  quantified  with  a fluorometric 
enzymatic  assay.  Results  are  expressed  as  means  ±  SD,  n=6.  *P  <  0.05  compared  with 
Control. 
 
 
 
 
 
 
 
 
 
 
Figure 4. Cholesterol Accumulation in Livers 
 
Immediately after animal sacrificed, livers were removed and heat processed. Weighed dried 
livers (300 mg) were extracted by chloroform: methanol (2:1, vol: vol) and stored at -20 C 
until analysis. Results are expressed as means ± SD, n=8. *P < 0.05 compared with Control.   
DISCUSSION: 
The  results  of  the  present  study  show  that  Lactobacillus  casei  dose-dependently  reduced 
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atherosclerotic plaque areas in apoE-deficient mice. The Lactobacillus casei thus has the 
capacity to prevent atherosclerotic plaque formation and progression in apoE-deficient mice. 
Genetic  knockout  of  apoE  gene  in  mice  has  shown  to  result  in  accumulation  of  plasma 
remnant  lipoproteins  and  development  of  atherosclerosis.  ApoE-deficient  mice  develop 
severe hypercholesterolemia and atherosclerosis on a regular chow diet [18-19]. Thus this 
mouse model has been widely used to investigate the atherogenesis and dietary intervention. 
The present study showed that after 16 weeks of dietary intervention, apoE-deficient mice 
group  exhibited  higher  serum  cholesterol  concentrations  which  in  turn  corresponded  to 
greater cholesterol accumulation in both liver and aortic tissue. Supplementation of diets with 
lactobacillus  casei  significantly  lowered  serum  TC,  TG,  LDL-C,  and  simultaneously 
enhanced HDL-C concentrations compared with the control group. In addition, Ataie-Jafari et 
al also evaluated the consumption of yoghurt containing L.acidophilus can decrease serum 
total cholesterol levels in mildly to moderately hypercholesterolemic subjects after 12 weeks 
[8].   
Mann and Spoerry were the first to report a hypocholesterolemic activity of fermented 
milk in Kenya′s Maasai tribe in 1974 [20].Thereafter, dairy products with some species of 
Lactobacillus acidophilus ATCC 43121 in rats [21], Bifidobacterium bifidum NRRL 1976 
[22]  and  Lactobacillus  in  hamsters  were  reported  [23].  In  addition  to  endogenously 
synthesised cholesterol, the absorption of dietary cholesterol and the reabsorption of biliary 
cholesterol  in  the  small  intestine  also  contribute  to  the  regulation  of  plasma  cholesterol 
concentrations. Moreover, reducing the intestinal absorption of dietary and biliary cholesterol 
can decrease plasma cholesterol concentrations [24].   
It has been proposed that the mechanisms underlying the hypocholesterolemic activity of 
probiotics can be attributed to the inhibition of the absorption of exogenous cholesterol in the 
small intestine by following mechanisms [25-26]. First, some strains of Lactobacilli casei 
may  survive  in  passage  through  the  acidic  stomach,  particularly  when  they  are  ingested 
together with other foods. The live Lactobacilli casei may change the gut bacterial content 
and colonization due to their adhesion to host intestinal epithelium, promote the proliferation 
of beneficial gastrointestinal indigenous microflora and prevent the growth or invasion of 
pathogenic bacteria into the animal intestine [27]. Second, these probiotic bacteria in the 
large  colon  may  ferment  unabsorbed  carbohydrates  to  produce  shortchain  fatty  acids, 
including  propionate,  which  lowers  cholesterol  by  inhibiting 
3-hydroxy-3-methylalutaryl-CoA reductase (HMG-CoA R) [10]. Cholesterol synthesis is a 
multienzyme pathway in which HMG-CoA reductase mediates the rate-limiting step. Third, 
live lactobacilli casei cells may bind and absorb cholesterol, reducing cholesterol absorption 
in the intestine and leading to reduced serum cholesterol levels [28]. Liong and Shah reported 
that  not  only  growing  cells,  non-growing  but  also  dead  lactobacilli  cells  could  remove 
cholesterol from media [29]. Fourth, these probiotic bacteria may suppress the reabsorption 
of  bile  acids  mediated  by  bacterial  bile  salt  hydrolysis  (BSH)  through  enterohepatic 
circulation  [30].  BSH  is  an  enzyme  that  catalyses  the  hydrolysis  of  glycine-  and 
taurine-conjugated bile salts into amino acid residues and free bile acids. Live lactobacilli and Functional Foods in Health and Disease 2014; 4(4):147- 158                                                 Page 155 of 158 
bifidobacteria cells can produce BSH, hydrolyze the conjugated bile acids, excrete them more 
rapidly,  and  reduce  the  extent  to  which  they  are  reabsorbed  [31].  The  increased  fecal 
excretion of bile acids leads to a decreased interohepatic circulation of bile acids, followed by 
an increase in conversion of cholesterol to bile acids in the liver and an increase in cholesterol 
uptake  from  the  circulation.  Furthermore,  a  very  recent  study  showed  that  the 
hypocholesterolemic effects of Lactobacillus acidophilus in rats are due to the reduction of 
cholesterol absorption mediated by the down-regulation of Niemann-Pick C1-Like 1 protein 
which  is  required  for  cholesterol  absorption  [7].  Whether  hypercholesterolemic  effect  of 
lactobacillus casei in present study is associated with decreased cholesterol absorption needs 
further investigation. 
Elevated cholesterol concentrations in the serum are associated with an increased risk of 
atherosclerosis and CHD, whereas a high concentration of serum HDL-C and a low ratio of 
TC to HDL-C are protective against CHD. A reduction as small as 1% in serum cholesterol 
concentrations has been shown to decrease the risk of CHD in human subjects by 2-3% 
[29].Elevated  serum  HDL  has  been  shown  negatively  correlated  with  the  risk  of 
atherosclerosis as HDL has an important role in cholesterol reverse transport by promoting 
cholesterol or cholesterol ester from peripheral tissues to the liver where cholesterol  was 
metabolized  and  transformed  into  bile  acids  [32].  This  pathway  represents  one  critically 
important mechanism for reducing cholesterol concentrations in both blood and peripheral 
tissues, thus protecting against atherosclerotic plaque formation. In addition, it is also note 
worthy that Lactobacillus casei supplementation decreased cholesterol deposition in tissues 
including liver and aorta which may explain for the reduced atherosclerotic plaque formation 
by lactobacillus casei. However, the possible molecular mechanism of lactobacillus casei 
affecting HDL and cholesterol accumulation in aorta and liver is still unknown and need 
further studies.   
In addition to the dyslipidemia, oxidative and elevated inflammatory response are also 
the important risk factor of atherosclerosis [33]. Several studies demonstrated that lactobacilli 
strains have the properties of inhibiting oxidative stress and elevated inflammation response. 
Amal S et al evaluated that lactobacillus casei and lactobacillus reuteri could protect against 
oxidative stress in rats which fed aflatoxins- contaminated diet [34]. And other research in 
antioxidant ability of lactic acid bacteria suggests that some lactic acid bacteria strains not 
only could decrease the risk of reactive oxygen species accumulation through food ingestion 
but also degrade the superoxide anion and hydrogen peroxide [35]. Suman Kapila reported 
that rats supplementation of 5% lyophilized culture or fermented milk prepared using L. casei 
ssp casei for a period of 90 days decreased cholesterol levels by 15-25%, simultaneously 
decreased the levels of TBARS in the LDL fraction of plasma [9]. In a pilot study of elderly 
person, the intestinal lactobacilli are tightly bound to WBC count, blood glucose and content 
of  oxidized  lipoprotein which  all  serve  as  risk  markers  in  pathogenesis  of  inﬂammation, 
metabolic syndrome and CHD. The particular species of probiotic lactobacilli could perform 
the benefits in terms of the health care of elderly people concerning the complex control of 
their  metabolic  and  systemic  inflammatory  and  oxidative  reactions  [36].  Therefore, Functional Foods in Health and Disease 2014; 4(4):147- 158                                                 Page 156 of 158 
Lactobacillus casei supplemented to apoE -/- mice in the present study may also inhibit the 
atherosclerotic plaque through improvement of oxidative stress and inflammatory response in 
addition to the improvement in lipid profile. 
 
CONCLUSIONS: 
The presence of Lactobacillus casei in diet was effective at decreasing atherosclerotic plaque 
development in aortic sinus in apoE-deficient mice. This cardio-protective effect was related 
to several mechanisms that corresponded to improving serum total cholesterol concentration 
and decreasing cholesterol accumulation in the liver and aortic arterial tissue.     
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